Hippocampal avoidance prophylactic cranial irradiation (HA-PCI) for small cell lung cancer reduces hippocampal atrophy compared to conventional PCI.
brain aging
brain injury
hippocampal atrophy
hippocampal avoidance prophylactic cranial irradiation
memory
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
05 01 2023
05 01 2023
Historique:
pubmed:
1
6
2022
medline:
11
1
2023
entrez:
31
5
2022
Statut:
ppublish
Résumé
Reducing radiation dose to the hippocampus with hippocampal avoidance prophylactic cranial irradiation (HA-PCI) is proposed to prevent cognitive decline. It has, however, not been investigated whether hippocampal atrophy is actually mitigated by this approach. Here, we determined whether HA-PCI reduces hippocampal atrophy. Additionally, we evaluated neurotoxicity of (HA-)PCI to other brain regions. Finally, we evaluated associations of hippocampal atrophy and brain neurotoxicity with memory decline. High-quality research MRI scans were acquired in the multicenter, randomized phase 3 trial NCT01780675. Hippocampal atrophy was evaluated for 4 months (57 HA-PCI patients and 46 PCI patients) and 12 months (28 HA-PCI patients and 27 PCI patients) after (HA-)PCI. We additionally studied multimodal indices of brain injury. Memory was assessed with the Hopkins Verbal Learning Test-Revised (HVLT-R). HA-PCI reduced hippocampal atrophy at 4 months (1.8% for HA-PCI and 3.0% for PCI) and at 12 months (3.0% for HA-PCI and 5.8% for PCI). Both HA-PCI and PCI were associated with considerable reductions in gray matter and normal-appearing white matter, increases in white matter hyperintensities, and brain aging. There were no significant associations between hippocampal atrophy and memory. HA-PCI reduces hippocampal atrophy at 4 and 12 months compared to regular PCI. Both types of radiotherapy are associated with considerable brain injury. We did not find evidence for excessive brain injury after HA-PCI relative to PCI. Hippocampal atrophy was not associated with memory decline in this population as measured with HVLT-R. The usefulness of HA-PCI is still subject to debate.
Sections du résumé
BACKGROUND
Reducing radiation dose to the hippocampus with hippocampal avoidance prophylactic cranial irradiation (HA-PCI) is proposed to prevent cognitive decline. It has, however, not been investigated whether hippocampal atrophy is actually mitigated by this approach. Here, we determined whether HA-PCI reduces hippocampal atrophy. Additionally, we evaluated neurotoxicity of (HA-)PCI to other brain regions. Finally, we evaluated associations of hippocampal atrophy and brain neurotoxicity with memory decline.
METHODS
High-quality research MRI scans were acquired in the multicenter, randomized phase 3 trial NCT01780675. Hippocampal atrophy was evaluated for 4 months (57 HA-PCI patients and 46 PCI patients) and 12 months (28 HA-PCI patients and 27 PCI patients) after (HA-)PCI. We additionally studied multimodal indices of brain injury. Memory was assessed with the Hopkins Verbal Learning Test-Revised (HVLT-R).
RESULTS
HA-PCI reduced hippocampal atrophy at 4 months (1.8% for HA-PCI and 3.0% for PCI) and at 12 months (3.0% for HA-PCI and 5.8% for PCI). Both HA-PCI and PCI were associated with considerable reductions in gray matter and normal-appearing white matter, increases in white matter hyperintensities, and brain aging. There were no significant associations between hippocampal atrophy and memory.
CONCLUSIONS
HA-PCI reduces hippocampal atrophy at 4 and 12 months compared to regular PCI. Both types of radiotherapy are associated with considerable brain injury. We did not find evidence for excessive brain injury after HA-PCI relative to PCI. Hippocampal atrophy was not associated with memory decline in this population as measured with HVLT-R. The usefulness of HA-PCI is still subject to debate.
Identifiants
pubmed: 35640975
pii: 6596101
doi: 10.1093/neuonc/noac148
pmc: PMC9825336
doi:
Types de publication
Clinical Trial, Phase III
Randomized Controlled Trial
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
167-176Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
N Engl J Med. 1999 Aug 12;341(7):476-84
pubmed: 10441603
JAMA. 2016 Jul 26;316(4):401-409
pubmed: 27458945
Br J Radiol. 2016;89(1057):20150762
pubmed: 26514377
Adv Radiat Oncol. 2017 Aug 30;2(4):624-629
pubmed: 29204530
Nat Rev Neurol. 2017 Jan;13(1):52-64
pubmed: 27982041
Neurology. 2017 Apr 4;88(14):1349-1357
pubmed: 28258081
Brain Struct Funct. 2014 Jan;219(1):255-67
pubmed: 23269366
J Thorac Oncol. 2021 Aug;16(8):e60-e63
pubmed: 34304857
Brain Imaging Behav. 2018 Aug;12(4):1112-1120
pubmed: 29063505
J Clin Oncol. 2011 Jan 20;29(3):279-86
pubmed: 21135267
Ann N Y Acad Sci. 2008 Mar;1124:1-38
pubmed: 18400922
Clin Transl Radiat Oncol. 2021 Aug 29;31:14-20
pubmed: 34504960
J Thorac Oncol. 2021 Aug;16(8):e63-e65
pubmed: 34304858
J Med Imaging Radiat Sci. 2019 Mar;50(1):119-128
pubmed: 30777232
N Engl J Med. 2007 Aug 16;357(7):664-72
pubmed: 17699816
Lancet Oncol. 2009 Nov;10(11):1037-44
pubmed: 19801201
Brain. 2010 Apr;133(Pt 4):1163-72
pubmed: 20375138
J Clin Oncol. 2021 Oct 1;39(28):3118-3127
pubmed: 34379442
Neuro Oncol. 2018 Apr 9;20(5):655-665
pubmed: 29112734
Clin Transl Oncol. 2019 Feb;21(2):178-186
pubmed: 29876759
Neuroradiology. 2018 Jun;60(6):617-634
pubmed: 29656321
Radiother Oncol. 2019 Jun;135:33-42
pubmed: 31015168
Neuroimage. 2012 Jul 16;61(4):1402-18
pubmed: 22430496
Neuro Oncol. 2013 Oct;15(10):1429-37
pubmed: 23956241
J Clin Oncol. 2014 Dec 1;32(34):3810-6
pubmed: 25349290
Magn Reson Imaging. 2021 Feb;76:108-115
pubmed: 33220450
J Thorac Oncol. 2021 Jun;16(6):e41-e42
pubmed: 34034889
J Clin Oncol. 2020 Apr 1;38(10):1019-1029
pubmed: 32058845
Nat Neurosci. 2017 Feb 23;20(3):353-364
pubmed: 28230844
Trends Cogn Sci. 2012 May;16(5):292-305
pubmed: 22542563
Neuroscience. 2018 Feb 10;371:506-517
pubmed: 29292073
Lancet Oncol. 2016 Jul;17(7):e277-e293
pubmed: 27396646
Neuroimage. 2020 Nov 1;221:117211
pubmed: 32739555
Neurobiol Aging. 2009 Nov;30(11):1711-23
pubmed: 18346820
J Clin Oncol. 2021 Oct 1;39(28):3093-3096
pubmed: 34379456
Eur J Cancer. 2020 Jan;124:194-203
pubmed: 31812935
Adv Radiat Oncol. 2021 Dec 11;7(6):100859
pubmed: 36420209
Cancer. 1977 Feb;39(2 Suppl):873-81
pubmed: 837351
J Thorac Dis. 2020 Oct;12(10):6225-6233
pubmed: 33209461
Lancet Oncol. 2017 Aug;18(8):1049-1060
pubmed: 28687377
Neuro Oncol. 2020 Jun 9;22(6):830-837
pubmed: 32002556
Eur J Neurosci. 2019 Dec;50(12):3921-3933
pubmed: 31370107
J Thorac Oncol. 2021 Jun;16(6):e42-e45
pubmed: 34034890
Neuroimage Clin. 2020;27:102287
pubmed: 32540630
Alzheimers Res Ther. 2015 Oct 15;7(1):61
pubmed: 26468086
Neurooncol Adv. 2020 May 21;2(1):vdaa060
pubmed: 32642712
J Thorac Oncol. 2021 May;16(5):840-849
pubmed: 33545387